Celularity (CELU) Non-Current Deferred Tax Liability (2019 - 2025)
Celularity (CELU) posted quarterly Non-Current Deferred Tax Liability of $3.0 million for Q4 2025, up 33300.0% year-over-year from N/an in Q4 2024, and up 33300.0% quarter-over-quarter from $9000.0 in Q3 2025.
Celularity (CELU) Non-Current Deferred Tax Liability (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 33300.0% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (up 33300.0% YoY), while the FY2025 annual figure was $3.0 million, up 33300.0% from the prior year.
- Non-Current Deferred Tax Liability rose to $3.0 million in Q4 2025 per CELU's latest filing, from $9000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.0 million in Q4 2025 and bottomed at $7000.0 in Q3 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $175611.1 across 5 years, with a median of $9000.0 in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability slipped 10.0% — and 2025, when it surged 33300.0%.
- Celularity's Non-Current Deferred Tax Liability stood at $10000.0 in 2021, then declined by 10.0% to $9000.0 in 2022, then changed by 0.0% to $9000.0 in 2023, then changed by 0.0% to $9000.0 in 2024, then soared by 33300.0% to $3.0 million in 2025.
- Business Quant data shows CELU's Non-Current Deferred Tax Liability at $3.0 million in Q4 2025, $9000.0 in Q3 2025, and $9000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.01 Mn |
| Dec 31, 2025 | 3.01 Mn |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 9,000.00 |
| Sep 30, 2023 | 9,000.00 |